Envista Holdings 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Envista reported Q3 2026 sales of $691 million, up $21 million year over year, with core sales growth of 2.7% and total growth of 3.2%.
- Adjusted EBITDA increased 9% to approximately $106 million, with an adjusted EBITDA margin of 15.3%, up 80 basis points; adjusted EPS was $0.40, up 25%.
- Adjusted gross margin reached 56.3%, up 20 basis points, and free cash flow was $63 million, representing 97% conversion of adjusted net income.
- Specialty Products and Technologies revenue was $444 million, up nearly 3%, with core growth of 2%; Equipment and Consumables delivered over 4% core growth, and adjusted operating profit in the segment increased more than 15%.
- Spark grew high single digits; diagnostics and implants grew mid-single digits, while consumables grew low single digits against a high 2025 comp.
- China business contracted at a low double-digit rate. China reduced revenue by approximately $7 million, primarily from orthodontics brackets and wires destocking ahead of VBP.
- The GAAP financials included a large noncash foreign currency gain in net income and EPS related to an international legal entity dissolution; it was not reflected in adjusted net income or adjusted EPS.
- Envista repurchased around 400,000 shares for roughly $10 million in Q3, and net debt to adjusted EBITDA was approximately 0.6 times.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Hello. My name is Angeline, and I will be your conference call facilitator this afternoon. At this time, I would like to welcome everyone to Envista Holdings Corporation's third quarter 2026 earnings results conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. If you would like to ask a question during that time, please press the star and then number 1 on your telephone keypad. If you would like to withdraw your question, please press the star and the number 2. I will now turn the call over to Mr. Jim Gustafson, Vice President of Investor Relations at Envista Holdings. Mr. Gustafson, you may begin your conference call.
Good afternoon. Thank you for joining Envista's third quarter 2026 earnings call. We appreciate your interest in our company. With me today are Paul Keel, our President and Chief Executive Officer, and Eric Hammes, our Chief Financial Officer. Our earnings release, the slide presentation supplementing today's call, and reconciliations and other information required by SEC Regulation G relating to any non-GAAP financial measures provided during the call are available in the Investors section of our website, www.envistaco.com. The audio portion of this call will be archived in the Investors section of our website later today under the heading Events and Presentations. During the presentation, we will describe some of the more significant factors that impacted year-over-year performance. The supplemental materials describe additional factors that impacted our results.
Unless otherwise noted, references in these remarks to company-specific financial metrics relate to the third quarter of 2026, and references to period-to-period increases and decreases in financial metrics are year-over-year. During the call, we may describe certain products and solutions that have applications submitted and pending certain regulatory approvals or are available only in certain markets. We will also make forward-looking statements within the meaning of the federal securities laws, including statements regarding events and developments that we believe or anticipate may occur in the future. These forward-looking statements are subject to a number of risks and uncertainties, including those set forth in our SEC filings, and actual results may differ materially from any forward-looking statements that we make today. These forward-looking statements speak only as of the date that they are made, and we do not assume any obligation to update any forward-looking statements except as required by law.
With that, I'll turn the call over to Paul.
Thanks, Jim, and hello to everyone joining us today. I will start with an overview of the quarter, including strategic and operational progress made in support of our longer-term value creation plan. Eric will then take us through the numbers in more detail. I will wrap things up with a few closing thoughts before we take your questions. As shown on slide four, we delivered core sales growth of 2.7% in Q3, with adjusted EBITDA growth of 9% and adjusted EPS growth of 25%. On a global scale, we did not observe any material shifts in the dental market in Q3 relative to the first half of the year. From a sector perspective, insurance-covered categories like prevention, diagnostics, and restoration displayed their characteristic resilience, while more elective categories like ortho and implants continued to run below their higher historical trends.
From a geographic perspective, developing markets, excluding China, continued to grow most quickly, followed by Europe. As indicated in the latest ADA survey, on a relative basis, the U.S. market remains soft, as macro uncertainty is impacting both patient and clinician confidence. China was also slow in Q3, as it is now in the middle of two dental VBP processes, of which I will say more shortly. Specific to our business, we continued to generate growth across the portfolio, with both reporting segments in all major geographies aside from China once again in positive territory. As has been the case now for the past several quarters, we converted good top-line performance into even stronger earnings growth. Behind continued factory and G&A productivity, gross and EBITDA margins grew 20 and 80 basis points respectively. EPS grew 25% in Q3 and is up more than 40% year-to-date.
Free cash flow conversion remained strong in the quarter, supporting continued share repurchases. Net debt to adjusted EBITDA now stands at 0.6 times. Based on our strong momentum and year-to-date performance, we are once again raising our full-year profit and EPS guidance. Our updated 2026 expectations call for core growth of 3.75%-4.25%, adjusted EBITDA growth of 12.5%-14%, and adjusted EPS of $1.54-$1.58, up more than 10% at the midpoint from our initial 2026 guide. Eric will say a bit more about the assumptions underlying our revised guidance in his section. Let's now turn to the progress we are making in support of our priorities of growth, operations, and people. Starting with growth, Spark was up high single digits. Diagnostics and implants were both up mid-single digits, and consumables grew low single digits against a high 2025 comp and following a strong H1.
Geographically, developing markets ex-China were up high single digits. Europe grew in the mid-single digits, and consistent with my earlier comments, North America was up low single digits. Coming back to China, as expected, our business contracted at a low double-digit rate in Q3, principally driven by preparations for VBP, which is now underway. We expected a roughly $10 million impact from VBP in Q3, and that is about how things played out. The latest government communications point to mid-December timing for results to be announced. Although, as we know, due to the complexity of these processes, VBP timelines often run long. We expect VBP implementation most likely to commence in the first half of 2027. Turning now to operations, we continue to make progress on multiple fronts, underpinned by our Envista Business System.
Our price, procurement, and factory productivity efforts once again offset inflationary pressures and helped to deliver growth and EBITDA margin expansion that I noted earlier. We continue to make good progress on the tax front as well, with our effective tax rate down in the quarter almost 6 points versus Q3 of 2025. With respect to people, progress also remains strong. Last quarter, we opened a new European design center for Spark in Madrid, complementing facilities already operating in North America and Asia. We conducted more than 40 Kaizen events in Q3, including a CEO Kaizen that I was honored to host, covering a half dozen projects across three continents. We also published our 2025 Sustainability Report, detailing the work we are doing to expand access to dental care, reduce environmental impact, and further increase investment in our colleagues and communities.
Specific highlights include a 17% year-over-year reduction in lost time injuries, a 19% reduction in water consumption, and a 40% reduction in waste generation. The report also outlines the important work we are doing through the Envista Smile Project, serving close to 20,000 patients last year alone. We further built on this momentum in Q3 of this year, delivering care across multiple U.S. locations, as well as internationally in Ghana, Mexico, Honduras, and Costa Rica. As we covered in some detail at our capital markets event in September, innovation is foundational to Envista's long-term growth strategy. We launched a number of new products across the first half of this year, and the momentum continued in Q3 with several additional high-impact introductions. Slide six highlights just three of these.
On the far left, NOMAD Pro 3 is the next generation of our handheld X-ray system that created the category, bringing high-quality imaging directly to the chair side. Pro three delivers improved image quality with optimized exposure presets designed to support faster, more consistent workflows. As safety is fundamental in imaging, NOMAD Pro 3 is engineered with multiple layers of protection and delivers 10 times less rear-directed radiation than the leading competitor. In the middle of the page is our new Ultra HDL Prismatic Loupe, the latest innovation from Orascoptic. Prismatic loupes are used by clinicians for more specialized procedures to achieve superior image clarity at higher magnification. The new Ultra HDL platform delivers this performance with a significantly lighter design, resulting in better ergonomics and greater comfort. Finally, the frame on the right provides an overview of our new Endo Module for DTX Studio.
This module uses AI-assisted canal segmentation to identify and characterize precise tooth anatomy. Resulting insights help customers with clinical decision-making, treatment planning, and patient communications. Root canal treatment is amongst the most common of endodontic procedures, with over 15 million performed last year in the U.S. alone. While general AI diagnostics are increasingly common in competitive systems, the depth and specificity of our latest Endo Module is unique and compelling. Early feedback from clinicians has been encouraging. Consistent with innovation's central role in our growth agenda, we have meaningfully increased new product investment each of the last two years. The returns from these investments in terms of growth, brand, and share gains are becoming increasingly clear. Our new product pipeline has never been richer, and we will continue to share our progress as programs develop.
Having now provided an overview of the quarter, I will turn the call over to Eric to walk us through the numbers.
Thanks, Paul. Third quarter sales were $691 million, up $21 million from the prior year. Core sales grew 2.7%. Total growth was 3.2%, with neutral FX and a slight tailwind from acquisitions. As Paul noted, growth was well-balanced across the portfolio by business, by geography, and between volume and price. Developed markets grew mid-single digits, while emerging markets grew low single digits all in, or high single digits excluding China. China declined double digits, driven by the orthodontics channel reducing inventories in preparation for VBP. Adjusted gross margin expanded, reaching 56.3% in Q3, a 20 basis point increase over last year that was driven primarily by price and factory productivity. Adjusted EBITDA increased 9% to approximately $106 million, with a margin of 15.3%, up 80 basis points.
Volume, price, and productivity each contributed to our profit growth and margin expansion, more than offsetting the headwinds from China, as well as our continued investment for growth. Adjusted EPS was $0.40, up 25% from Q3 of last year, driven by both improved operating profitability and a lower tax rate. You may have noticed that the GAAP financials in our earnings release reflect the realization of a large foreign currency gain in net income and EPS. This gain is the result of an international legal entity dissolution, which relates to the significant intercompany loan resolution announced in Q3 of last year. Overall, this change aligns with our strategy of simplifying our legal entity structures. Important to note, the GAAP gain was a non-cash event and is not reflected in our adjusted net income or adjusted EPS.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
12 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
